Septerna is a biochemical drug discovery company. With GPCR scientists, Septerna is focused on researching G protein receptors to develop new medicines in the pharmacology field. The company also features drug-screening technology, modular assemblies, and Silico molecule screening. Septerna was founded by Arthur Christopoulos, Jeffrey Finer, Patrick Sexton, and Robert Lefkowitz in 2022 and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/11/2023 | Series B | $150MM | $xx.xx | $313.42MM | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | |
Price per Share
$xx.xx
Shares Outstanding
121,657,452
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital
|
||||||
01/27/2022 | Series A | $75MM | $xx.xx | $150MM | Third Rock Ventures, Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, Logos Capital | |
Price per Share
$xx.xx
Shares Outstanding
75,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Third Rock Ventures, Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, Logos Capital
|